HIFU has been trialed on several types of cancers including prostate cancer, breast cancer (limitations), malignant bone tumors, liver cancer, kidney cancer, carcinoma of the bladder, pancreatic cancer and reoccurrence of a solid tumor post conventional surgery.
BioMaxx Partnership
The BioMaxx Therapy Systems Co., Ltd. is the first HIFU-user and distributor in Southeast Asia. BioMaxx created a distribution partnership with Beijing RDS HIFU.
Beijing RDS Technology has a very strong R&D team that consists of senior scientists who once worked at the Chinese Academy of Sciences, the No.9 Institute of Ministry of Nuclear Industry, various universities in Beijing, and related academies and hospitals. With unique scientific concepts and processing techniques, the RDS Group has successfully produced the RDS-HIFU Tumor Therapy System. The Beijing RDS Technology Co., Ltd. has been granted independent intellectual property rights and has acquired several national invention patents. Its advancements effectively solve problems such as the need for anesthesia and localized tissue carbonization. These unique improvements specific to RDS-HIFU Tumor Therapy system are a significant breakthrough in the latest tumor treatment methods.
RDS has a comprehensive quality control system, professional management team, and efficient after-sales service. With the philosophy of meeting the spoken and unspoken needs of patients and the commitment of “Safety, Efficiency, Sincerity, and Innovation,” we are dedicated to providing state-of-the-art, more secure, and more effective tumor therapy systems to medical experts in order to promote the advancement of cancer therapies. We sincerely hope to partner with professionals from every industry to jointly provide new and effective treatment options for tumor patients! Based on the core technologies BioMaxx has been devoted to the development and application of high intensity focused ultrasound (HIFU) tumor therapy equipment and has been approved by the Beijing Science and Technology Committee as a high-tech enterprise.
Principles about HIFU
HIFU Principles
The HIFU technology intensely focuses ultrasound waves on a targeted tissue, rapidly increasing temperature at focal point to achieve tissue ablation without damaging surrounding tissues.
RDS-HIFU is an innovative system which adopts a unique multi-axis motion transducer. The bowl shaped transducer is concentrically lined with 30 ultrasonic emitters and is fitted with an imaging probe to achieve high precision image guided tumor location and ablation system.
RDS-HIFU is an innovative system which adopts a unique multi-axis motion transducer. The bowl shaped transducer is concentrically lined with 30 ultrasonic emitters and is fitted with an imaging probe to achieve high precision image guided tumor location and ablation system.
History
- In 1942, Dr. Lynn introduces the HIFU concept. But in the 1970’s, Dr. Fry partners with Tumor Specialist, Dr. Heimburger, to introduce HIFU as a tumor treatment technology.
- In June 2002, HIFU Research Institute of Oxford University affirms the efficacy and safety of using HIFU Technology to treat liver cancer and renal carcinoma.
- In July 2003, China issues the world’s first national technical HIFU standard -------“Technical Requirements for HIFU Therapy Device”.
- In December 2004, National Institute for Clinical Excellence (NICE) recommended HIFU technology for treating prostate cancer.
- In 2004, Wall Street Daily awards “Bronze Medal for Technology Advancement” to HIFU Tumor Treatment System.
- In October 2004, American FDA approved HIFU for treating uterine fibroid.
Some Information about HIFU System
1.Central Control Console
 |
 |
Consists of RDS Treatment Control System, RDS Treatment Planning System, and an integrated B-Scan.
The Console processes data (such as tumor space, position, size, depth from skin to targeted tumor area, and surrounding circumstances), adjusts the ultrasound power, controls the treatment bed movement system, and monitors treatment area in real-time. |
2. Treatment Bed Movement Control System
Consists of a multi-arrayed transducer, treatment platform, and multi-axis motion system, which mechanically mobilizes the patient into optimal position for treatment.
3. Water Degassing System
Consists of a water level controller, vacuum processor and temperature control system to remove air from and to heat the water. This is critical for decreasing the attenuation of ultrasound wave, and providing a comfortable water temperature for the patient.
4. Power Supply System
Provides 30 independent, separately adjustable 1MHz electrical current to the transducer to achieve focal area acoustic intensity which is continuously adjustable between 1kW/cm2 and 10kW/cm2
Technical Specification & Working Environment
- Working Frequency: 1MHz+/-15%
- Acoustic Intensity in the Focal Area: 1kW/cm2~10kW/cm2 continuously adjustable
- Focal Area: ● 2mm≠8mm
- Scanning Mode: sequence or pulse
- Treatment Penetration: (10~180) mm
- Water Consumption: <70L/Patient
- Power Supply: 220V, 50Hz, 15 kVA
- Required Working Area: ◎40m2
- Required Working Temperature: (25~30)→
Mechanisms of RDS-HIFU Tumor Therapy
- Thermal Effect
Increases the temperature of the focal area to 70→-100→ instantaneously, causing tumor cell ablation.
- Cavitation Effect
The ultrasound amplitude pressure on the targeted area destroys the microscopic structure of the tumor cell, causing cell necrosis.
- Mechanical Effect
The mechanical movement of high-energy ultrasound waves dramatically damages the tumor cell membrane and internal structure, causing the tumor cell to lose its structural strength.
- Fields Effect
Generated by the chemical reactions between acoustic field and biological field, the chemical energy on the targeted area changes the cell's membranous structure.
- Damage to tumor-nourishing blood capillaries
Destroys the blood capillaries below 200―500┢m, causing the tumors secondary ischemic necrosis.
Working Principle
Signal generators produce 1MHz electrical currents that are amplified before transducers transform them to 1MHz ultrasonic waves. Focusing multiple ultrasonic waves create a localized, high temperature field.
Our Treatment Control System guides the transducers to blast precisely controlled intervals of highly focused ultrasonic waves to achieve a localized high temperature zone that quickly heats targeted tumor cells until resulting coagulation necrosis. Our transducers use point-to-line, line-to-slice, and slice-to-solid treatment methods to achieve total 3-D tumor cell shape conformation.
Unique Characteristics of RDS-HIFU Transducer
- Achieves a pain-free tumor ablation without use of anesthesia through our transducer. Having large incidence angle of over 100▲, our transducer reduces the acoustic intensity of the ultrasonic energy that passes through the skin to achieve tissue ablation on the target area while keeping the skin surface below 40→.
- Small Focal Area (1.5mm≠6mm), integrated with the real-time monitoring and positioning systems, to achieve more accurate 3D conformal treatment.
- Dual-focusing with centralized focal point, to instantly increase the focal area temperature in order to cause coagulate necrosis of tumor cells.
- Low side-lobe and lower energy waste. The HIFU energy beams precisely focuses on the targeted area within the body without damaging surrounding tissues. Patients are treated without anesthesia, speedy recovery.
- Focal area acoustic intensity is continuously adjustable between 1kW/cm2 and 10kW/cm2, allowing various treatment depths and tissue types, that provide flexible patient dosage for effective treatment.
- The transducer has a broad treatment penetration range of between 10mm and 180mm, and can be precisely shifted horizontally, vertically, as well as rotated on its x-axis, thus accommodating wider treatment modes and positions. The intensity of each of the emitters can be controlled separately to steer clear of certain ribs and important organs.
Clinical Application
All the tumors in the pelvic or peritoneal areas and body surface which can be observed by the digital ultrasound scanner can be treated．The Clinical Applications are classified into 2 groups:
- Malignant Tumors: liver cancer, kidney cancer, pancreatic cancer, rectum cancer, bladder cancer, prostatic cancer, breast cancer, sarcoma of uterus, tumors in limbs and sarcoma in soft tissue.
- Benign Tumors: hysteromyoma, hyperplasia of mammary glands, prostate hypertrophy, benign tumor of soft tissue.
|
 |
Clinical Application
Clinical Cases
The clinical trials conducted on thousands of tumor patients during many years have indicated that the RDS-HIFU tumor Therapy systems have achieved outstanding effects on the application of both malignant tumors and benign tumors. It has effectively achieved the ability to administer the treatment without anesthesia, trauma, pain, and the need for invasive operation. Furthermore, treatment with the RDS machine will not cause damage to healthy tissues surrounding the tumor. These unique features are a massive leap forward in HIFU technology!
Ms. Han, 64 Years Old, Tonghua City, Jilin Province
Symptoms: The patient had left kidney excision in 1993. In September 2004, she felt pain in the right kidney accompanied by hematuria, diagnosed with right renal pelvis carcinoma.
Outcome: On December 21st, 2004, she received RDS-HIFU therapy twice (one week interval). The pain disappeared and urine routine backed to normal. On March 8th, 2005, the check-up showed tumor coagulation necrosis, size shrank from 4.2≠2.3≠2.7cm to 3.6≠2.0≠1.8cm.
Mr. Li 51 Years Old, Handan City, Hebei Province
Symptoms: Poor appetite and a lack of strength up until October 2004. Then the symptoms became more severe and whole skin became yellow and he was diagnosed with pancreatic cancer.
Outcome: Prior to RDS-HIFU therapy the size of the tumor was 3.2≠3.0cm, two months after the treatment in 2005, the tumor shrank to 1.5≠1.6cm, the patient had gained 2kg. In the most recent follow up in March 2006, the patient’s health condition is stable.
Mr. Wei 53 Years Old Inner Mongolia Autonomous Region
Symptoms: In August 2004, pain in liver area and flatulency occurred, and he was diagnosed with primary liver cancer. The size of the tumor was 3.8≠4.2cm.
Outcome: One week after the patient received RDS-HIFU treatment in November 2004. The discomforts disappeared. In May 2006, the CT-scan demonstrated no abnormity in the liver area.
Ms. Zhang, 36 Years Old, Weifang City,Shandong Province
Symptoms: The patient was diagnosed with adenomyoma of uterus ten years ago. The size of the tumor was 5.5≠5.3cm.
Outcome: Local coagulation necrosis can be seen (5.5≠5.3cm) right after the treatment. Two months after the treatment in 2006, dysmenorrheal symptom had disappeared. |
